Lenvatinib丨CAS 417716-92-8

Lenvatinib丨CAS 417716-92-8
Product Introduction:
Catalog No.: SS129689
CAS No.: 417716-92-8
Purity: 99.0%min
Product Name: Lenvatinib
Molecular Formula: C21H19ClN4O4
Molecular Weight: 426.85
Synonym(s): Lenvima
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of lenvatinib丨cas 417716-92-8 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Character: Off-white to white powder
Purity: 99.0% min
Loss on drying: 0.5% max
Residue on ignition: 0.5% max
Unspecified impurity: 0.2% max
Total impurities: 1.0% max

 

Transport Information

 

Parameter

Specification

UN Number

 

Class

 

Packing Group

 

H.S. Code

2924199090305

Stability & Reactivity

The product is chemically stable under standard ambient conditions.

Storage

-20°C

Condition to Avoid

 

Package

 

 

 

 

Applications

 

1. Cancer Treatment

Lenvatinib is a targeted anticancer drug used in the treatment of various solid tumors. It is approved for use in several types of advanced or metastatic cancers, including:

■ Thyroid Cancer

Approved for radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).

Improves progression-free survival compared to placebo.

■ Hepatocellular Carcinoma (HCC)

Used as a first-line therapy for unresectable liver cancer.

Shown to be non-inferior to sorafenib in clinical trials (e.g., REFLECT trial).

■ Renal Cell Carcinoma (RCC)

Used in combination with everolimus or pembrolizumab for advanced RCC.

Offers improved objective response rate and overall survival.

■ Endometrial Cancer

Approved in combination with pembrolizumab for advanced or recurrent endometrial carcinoma not responsive to conventional therapy.

 

Benefits

 

1. Targeted Therapy

Specifically acts on cancer-driving pathways, minimizing damage to normal cells compared to traditional chemotherapy.

2. Broad Antitumor Activity

Effective across multiple cancer types due to its multi-target inhibition.

3. Oral Administration

Given as a daily oral capsule, which is more convenient than intravenous therapies.

4. Synergistic in Combination Therapy

Potentiates the efficacy of immunotherapies (e.g., pembrolizumab), enabling combinatorial treatment approaches.

5. Improved Clinical Outcomes

Increases progression-free survival (PFS) and overall response rate (ORR) in several cancer types.

Often a first-line choice when surgery is not feasible or disease is refractory to standard care.

 

Conclusion

 

Lenvatinib (CAS 417716-92-8) is a potent, multi-targeted kinase inhibitor used in modern oncology. It plays a critical role in the treatment of thyroid, liver, kidney, and endometrial cancers by inhibiting angiogenesis and tumor cell proliferation. Its effectiveness, particularly when combined with immunotherapy, makes it a cornerstone in the management of several difficult-to-treat cancers.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us